Life Science

17-phenyl trinor PGD2 is a novel, chemically stable analog of PGD2 wherein the lower side chain is modified by the addition of a phenyl group at C-17 in place of the last 3 &omega-chain carbon atoms. This modification has not been reported in a

17-phenyl trinor PGD2 is a novel, chemically stable analog of PGD2 wherein the lower side chain is modified by the addition of a phenyl group at C-17 in place of the last 3 &omega-chain carbon atoms. This modification has not been reported in a

17-phenyl trinor PGD2 is a novel, chemically stable analog of PGD2 wherein the lower side chain is modified by the addition of a phenyl group at C-17 in place of the last 3 &omega-chain carbon atoms. This modification has not been reported in a

Derived from 17-phenyl trinor PGE2, a synthetic analog of PGE2 that acts as an agonist of EP1 and EP3 in mice (Ki = 14 and 3.7 nM, respectively) and EP1, EP3, and EP4 in rats (Ki = 25, 4.

Derived from 17-phenyl trinor PGE2, a synthetic analog of PGE2 that acts as an agonist of EP1 and EP3 in mice (Ki = 14 and 3.7 nM, respectively) and EP1, EP3, and EP4 in rats (Ki = 25, 4.

17-phenyl trinor PGE2 is a synthetic analog of PGE2. It is an EP1 and EP3 receptor agonist.

17-phenyl trinor PGE2 is a synthetic analog of PGE2. It is an EP1 and EP3 receptor agonist.

17-phenyl trinor PGE2 is a synthetic analog of PGE2. It is an EP1 and EP3 receptor agonist.

17-phenyl trinor PGE2 is a synthetic analog of PGE2. It is an EP1 and EP3 receptor agonist.

The 1,15 lactone of 17-phenyl-trinor PGF2&alpha with potential for suitable pharmacologic activity and an improved side-effect profile over current glaucoma therapeutics.

The 1,15 lactone of 17-phenyl-trinor PGF2&alpha with potential for suitable pharmacologic activity and an improved side-effect profile over current glaucoma therapeutics.

The 1,15 lactone of 17-phenyl-trinor PGF2&alpha with potential for suitable pharmacologic activity and an improved side-effect profile over current glaucoma therapeutics.